Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Immune responses can be generated locally within human melanoma skin metastases
• Immune cell activation seen in skin metastases from melanoma patients
• Structures supported active B lymphocyte responses
July 31, 2012, Philadelphia, PA—In many types of cancer, activated immune cells infiltrate the tumor and influence clinical outcome. It is not always clear where these cells are activated, but results reported in Cancer Research, a journal of the American Association for Cancer Research, indicate that in a subset of patients with metastatic melanoma, they can be activated in the tumor microenvironment.
“Our data provide a new concept in melanoma,” said Nicolas van Baren, M.D., Ph.D., a clinical and laboratory investigator at the Ludwig Institute for Cancer Research, the de Duve Institute and the Cancer Centre of Cliniques universitaires Saint-Luc in Brussels, Belgium. “Before we began our study, it was thought that immune responses were triggered in specialized structures known as lymph nodes. Lymphocytes, which are an important subset of immune cells, became activated in lymph nodes and then migrated via the blood to the tumor.”
Results of his study showed an alternative path whereby naive lymphocytes were activated locally in the tumor microenvironment. “Fundamental knowledge like this is crucial as we seek to understand how tumors escape antitumor immune responses and how we can develop approaches to counter this,” he said.
For the majority of immune responses mounted by our bodies, for example in response to invading microbes, the predominant sites of lymphocyte activation are the lymph nodes, spleen and mucosal-associated lymphoid tissues. All these sites are dedicated to supporting the initiation and maintenance of immune responses. However, in some instances of chronic infection, for example with hepatitis C virus, ectopic lymphoid structures, or lymphoid structures that resemble lymph nodes and develop at aberrant locations, form at the site of the infection and locally support lymphocyte responses directed against the infectious agent.
Ectopic lymphoid structures have also been observed in some malignant tumors, including breast, lung and colorectal tumors, but not melanoma. In some studies, their presence has been linked to improved prognosis.
Van Baren and colleagues observed ectopic lymphoid structures in seven out of 29 skin metastases from patients with melanoma. In contrast, no primary melanoma samples examined contained complete ectopic lymphoid structures. However, some of them hosted small blood vessels that are associated with these structures.
Further analyses indicated that the ectopic lymphoid structures were functional, as features indicative of activation of the B cell lymphocyte subset were observed.
“It is important to have established that immune responses can be generated locally, at least in skin metastases,” said van Baren. “In fact, this last point, that we detected functional lymphoid structures in skin metastases and not in primary tumors, is extremely intriguing. We think that understanding the reasons for this difference will be highly informative in determining how antimelanoma immune responses develop during disease progression.”
The sample size was too small to allow the researchers to draw clinically meaningful conclusions. “Nonetheless, it will be important to look at this moving forward, as it is not yet clear whether these structures are good for the patient and bad for the tumor or good for the tumor and bad for the patient. At this point, there is no indication either way, and we could provide a speculative argument for either.”
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.